

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
August 18, 2016

---

**MRI INTERVENTIONS, INC.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**000-54575**  
(Commission  
File Number)

**58-2394628**  
(I.R.S. Employer  
Identification Number)

**5 Musick**  
**Irvine, Ca. 92618**  
(Address of principal executive offices, zip code)

**(949) 900-6833**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01. Regulation FD Disclosure**

On August 18, 2016, MRI Interventions, Inc. (the “Company”) posted an updated investor presentation to its website at <http://ir.stockpr.com/mriinterventions/investor-presentation>. A copy of the investor presentation is being furnished herewith as Exhibit 99.1. The Company may use the investor presentation from time-to-time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The information contained in Exhibit 99.1 is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make from time-to-time, by press release or otherwise. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time-to-time as its management believes is warranted. Any such updating may be made through the filing or other reports or documents with the SEC, through press releases or other public disclosure.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit 99.1 MRI Interventions, Inc. Investor Presentation dated August 18, 2016

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 18, 2016

**MRI INTERVENTIONS, INC.**

By: /s/ Harold A. Hurwitz  
Harold A. Hurwitz  
Chief Financial Officer

---

## INDEX TO EXHIBITS

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
Exhibit 99.1	MRI Interventions, Inc. Investor Presentation dated August 18, 2016

---



Ticker: MRIC

***Investor Presentation***

August 18, 2016



***Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI***

Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; availability and adequacy of reimbursement from third party payors for procedures utilizing our products; the sufficiency of our cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; the impact of the commercial and credit environment on us and our customers and suppliers; and our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, our ClearTrace system. More detailed information on these and additional factors that could affect MRI Interventions' actual results and the timing of events are described in its filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements made in this presentation to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statements are based.

## Commercial Business

- **Focused commercial effort in neurosurgery; FDA/CE cleared products**
  - Enabling real-time MRI guided surgery; FDA-cleared, CE-marked and 45+ ClearPoint sites; growing procedure business

## Drug Delivery Upside

- **Growing Presence in Drug Delivery**
  - ClearPoint System now in 7 clinical trials; biotech like upside

## Investment Timing

- **Restructuring complete; operating cash burn dramatically lower. Several near-term milestones:**
  - 1 for 40 reverse split completed in July 2016
  - St. Jude's entry into the DBS market in the US – Q3/Q4 2016\*
  - Voyager reports results of first 10 patients – Q4, 2016\*
  - UniQure initiates second cohort of Phase 1 trial – Q1, 2017\*
  - Additional drug delivery partnerships under evaluation

\* Estimated date

# Experienced, Medical Device Leadership Team



## Key Management

<i>Executive</i>	<i>Title</i>	<i>Prior Experience</i>
Frank Grillo	President, CEO	INTUITIVE SURGICAL™, KYBLON- Boston Scientific
Peter Piferi	COO	Edwards, HeartWare, Cordis
Wendelin Maners	VP Marketing	Boston Scientific, CSA MEDICAL
Robert Korn	VP Sales	Medtronic, Codman
Hal Hurwitz	CFO	pwc, ev3


## Board of Directors

<p>Kimble Jenkins, Chairman</p> <p>Morgan Keegan</p>	<p>Maria Sainz</p> <p>CARDIOKINETICS</p> <p>concentric</p> <p>stryker</p> <p>GUIDANT</p>	<p>Dr. Phillip Pizzo</p> <p>STANFORD SCHOOL OF MEDICINE</p>	<p>Pascal Girin</p> <p>WRIGHT</p> <p>ev3</p>	<p>Timothy Richards</p> <p>VNUS</p> <p>COVIDIEN</p> <p>B BRAUN</p> <p>SHARING EXPERTISE</p>	<p>Frank Grillo, CEO</p> <p>Boston Scientific</p> <p>KYBLON-</p> <p>INTUITIVE SURGICAL™</p>
	<p>Jack Spencer</p> <p>ERNST &amp; YOUNG</p>	<p>Charles Koob</p> <p>Simpson Thacher</p>	<p>Andrew Rooke</p> <p>Major Investor</p>		



# ClearPoint® Neuro Navigation System

Utilizes an existing diagnostic or intraoperative MRI to enable real time, intra-operative MRI Imaging during Neurosurgery



- **ClearPoint Software**

- Proprietary software for targeting and trajectory calculation / determination
- Dicom image based

- **MRI Safe Hardware**

- MRI safe head fixation frame, monitor, other components for the procedure

- **SmartFrame®; SmartGrid®**

- Single use devices, with MRI fiducials “seen” in MRI images, enable targeting and trajectory calculations
- Proprietary drape for creating sterile environment
- Per procedure revenue

**Compatible with All Major MRI Platforms**

SIEMENS

PHILIPS

GE Healthcare

IMRIS

BrainSUITE

# Key Procedures for Our Technology

...and the challenges we address



Therapies	Patient Populations	Key Challenges We Address
<b>Deep Brain Stimulation</b> Medtronic St. Jude* Boston Scientific*	<b>Parkinson's Disease</b> <b>Dystonia</b>	<ul style="list-style-type: none"> <li>65% plus opt-out rate for DBS due to fear of surgery itself</li> </ul>
<b>Laser Ablation</b> Visualase/Medtronic Monteris	<b>Epilepsy</b> <b>Brain Tumor</b>	<ul style="list-style-type: none"> <li>Two room procedure</li> <li>Patient transport mid-procedure</li> <li>Accuracy of ablation is critical</li> </ul>
<b>Drugs/Biologics</b> Voyager UniQure Merrimack Int'l Stem Cell Medicenna Plus others	<b>Parkinson's Disease</b> <b>Brain Tumor</b>	<ul style="list-style-type: none"> <li>Precise, Controlled Delivery is Essential</li> <li>Drug diffusion visualization is a must have</li> <li><i>Need for ClearPoint underscored in Voyager S-1</i></li> </ul>

# Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind”



## Conventional Stereotactic Procedure




No real time images – images from earlier in the day or week

## ClearPoint Neuro Procedure



diagnosing in the correct alignment using real-time MRI






80% of interviewed neurosurgeons/neurologists believe real time MRI-guidance will or can become the future of functional neurosurgery. (\*)

\*Interviews conducted by a third party on behalf of MRI Interventions (n=36)


# ClearPoint Procedure Overview



## Target Selection & Entry Planning



SmartFrame® Trajectory Guide



SmartFrame® Hand Controller



## Trajectory Alignment & Device Insertion





## ***Notable Neurosurgeon Supporters***



Dr. Philip Starr  
ASSFN Past  
President



Dr. Paul Larson  
UCSF & VA



Dr. Robert Gross  
Emory University



Dr. Robert Wharen, Jr.  
Mayo Clinic -  
Jacksonville




Dr. Krys Bankiewicz  
Bankiewicz Lab, UCSF



Dr. Russ Lonsler  
OSU - NIH

## ***Published Peer-Reviewed Journal Support***



# Patented Intellectual Property

*Over 100 issued patents around the world*




70+ U.S. Patents

45+ OUS Patents

20+ U.S.  
Patent Applications

30+ OUS  
Patent Applications



- ***Issued patents cover areas such as:*** MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide; other ClearPoint® disposable components; active intracranial probes; MRI-compatible catheters and Hand Drill; MRI-safety technology; Scalp Mount Base
- Key ClearPoint-related patents do not begin to expire until 2027


# MRIC's Unique Opportunity in Drug Delivery

## Major Challenges in Delivering Drugs to the Brain

- Blood brain barrier blocks systemic delivery (pills, shots, IV) of almost all drugs – 98% of small molecules
- Direct injection without ClearPoint is blind, so target is frequently missed
  - *Neopharm Trial - 51% of 572 catheters failed to meet all positioning criteria*

## Major Benefits of Drug Delivery with ClearPoint

- Neurosurgeon sees that target is reached
- Eliminates the blood brain barrier issue
- Reduces/eliminates unwanted systemic side effects
- Reduces dosage levels (as little as 1/300th of systemic volume)



## Business Model – MRIC Partners with Drug Companies and Researchers

- MRIC provides ClearPoint; Drug company provides drug candidate
- Drug company/sponsor pays for trial
- If drug is approved, MRIC gets device revs (~\$7000/case); Drug co gets drug revs

Provides MRIC with “biotech-like upside” without “all or nothing downside”




# ClearPoint Drug Delivery w/ SmartFlow Cannula



- MR visualization of neuro target
- MR-guided placement of catheter
- Therapeutic agent delivered under MR-guidance\*



Specialized, FDA-cleared drug delivery cannula's / catheters



Drug infusion is visible under real-time MRI

## Growing Set of Peer-reviewed Publications...

**Laboratory Investigation**

Striatal Functional Neurosurgery

Mark Richardson, PhD, et al.

**Novel Platform for Enhanced Delivery Validation in Non-human Primate**

**Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease**








**Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery to be performed with a high level of precision, predictability, and safety.**

# ClearPoint's Use in Drug Delivery

## Seven Programs Underway Now...




### Current Drug Delivery Trials Utilizing the ClearPoint System:

	<b>AAV2-hADC for Parkinson's disease</b> <ul style="list-style-type: none"> <li>Phase 1 Study at UCSF</li> <li>Initial sponsorship by Michael J. Fox Foundation</li> </ul>		<b>IL13 for Brain Tumor</b> <ul style="list-style-type: none"> <li>Phase 1 study at the NIH</li> </ul>
	<b>AAV2-GDNF for Parkinson's disease</b> <ul style="list-style-type: none"> <li>Phase 1 Study at the NIH</li> </ul>		<b>Radio Immunotherapy for Brain Tumor</b> <ul style="list-style-type: none"> <li>Phase 1 Study at MSK</li> </ul>
	<b>MDNA55 for Recurrence or Progression of Glioblastoma</b> <ul style="list-style-type: none"> <li>Preparing Phase 2</li> </ul>		<b>Nanoliposomal Irinotecan for Brain Tumor</b> <ul style="list-style-type: none"> <li>Phase 1 Study at UCSF</li> </ul>
	<b>Human Parthenogenetic Stem Cell-Derived Neural Stem Cells for Parkinson's disease</b> <ul style="list-style-type: none"> <li>Pre-clinical leading to Ph. 1</li> </ul>		

*The ClearPoint System is being used in the ongoing Phase 1b clinical trial of VY-AADC01 as a treatment for advanced Parkinson's disease, and we expect to continue to use the ClearPoint System in future clinical trials of VY-AADC01 and any other of our product candidates that are injected directly into the brain. IPO S-1, Voyager Therapeutics*


## BUSINESS MODEL – RAZOR / RAZORBLADE

- ClearPoint Hardware/Software: \$100,000 - \$150,000 ASP
- ClearPoint Disposables: \$7,500 (average) ASP per procedure with potentially strong margins
- Recurring revenue from the sale of disposables
- Procedures covered by existing inpatient DRG reimbursement codes



# Growing the ClearPoint Footprint

Installed Base of 44 sites in the US



Europe: Warsaw, Poland

	<u>Parkinson's</u>	<u>Epilepsy</u>	<u>Brain Tumors</u>
Total Prevalence (US)	1,500,000	2,200,000	80,000 (annual diagnosis)
Prevalence – Drug Treatment Resistant (DTR)	125,000	264,000	
Incidence – DTR	7,500	18,000	Resections: 80,000 Stereotactic Biopsy: 10,000
ClearPoint Enabled Therapy	Electrode Placement (DBS)	Laser Ablation RNS <sup>1</sup>	Biopsy / Laser Ablation / Drug Delivery
Potential ClearPoint Procedures, Annually <sup>2</sup>	12,500	28,000	14,500


## 55,000+ Potential Procedures Per Year

Note: Prevalence and Incidence based on either market research conducted by a third party on behalf of MRI Interventions or research conducted by MRI Interventions of publicly available sources.

(1) Responsive neurostimulation device (RNS)


(2) Potential Annual ClearPoint Procedures based upon 5% of prevalence and 85% of incidence; Potential Annual ClearPoint Procedures for brain tumors based on market research conducted by a third party on behalf of MRI Interventions.

# ClearPoint Consumable Revenues







## Total Revenue, 2013 - 2016



# Cash Flow From Operations









**Ticker: MRIC**

MRI Interventions, Inc.  
Irvine, CA

949.900.6833

[www.mriinterventions.com](http://www.mriinterventions.com)



***Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI***

© 2016 MRI INTERVENTIONS, INC. | 22